Mesenchymal stem cell therapy may supress side effects from cancer drugs
In a new study, researchers from Osaka University have highlighted that mesenchymal stem cells could repress type 1 diabetes caused by cancer drugs.
List view / Grid view
In a new study, researchers from Osaka University have highlighted that mesenchymal stem cells could repress type 1 diabetes caused by cancer drugs.
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
A new study has shown that cilia-free human pluripotent stem cells could help scientists understand the causes of polycystic kidney disease and other cilia-linked illnesses.
Neuroscientists have designed brain organoids to contain both mature neurons and astrocytic glial cells in relative proportions like the human brain.
Researchers have discovered that failed epigenetic suppression of an X-chromosome gene called Xist leads to miscarriage and developmental abnormalities.
Researchers have found new ways to artificially induce mRNA to respond in ways that could eventually lead to therapeutic outcomes.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
Scientists report news of a promising new compound that effectively blocks the activity of proteins on cells that are necessary for SARS-CoV-2 to cause infection.
The antigen-based vaccine has the potential to induce sterilising immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry.
Researchers have developed a novel substance that disables a protein in the cell skeleton, leading to cell death. In this way, substances of this type can prevent the growth of tumours.
Columbia-led team wins research grant to create fundamentally new maps that will chart cell diversity throughout the brains of humans.
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
Scientists have found that molecules produced by cells in response to stress may be indicators of various diseases.
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.